What Are Induced Pluripotent Stem Cells?
Scientists have long sought to understand how cells develop and how disease disrupts that process. Stem cell research became a vital tool for answering these questions. For many years, researchers relied on embryonic stem cells. However, their use raised serious ethical concerns, especially when human embryos were involved.
The discovery of induced pluripotent stem cells (iPSCs) changed everything. iPSCs are adult somatic cells that scientists can reprogram to behave like embryonic stem cells. Crucially, they can give rise to virtually any cell type in the human body. Furthermore, they sidestep the ethical issues surrounding embryonic stem cells entirely. Today, iPSCs drive advances in disease modeling, drug discovery, and cell-based therapies.
2006: Yamanaka Factors Change Everything
A Breakthrough Announced at a Conference
In spring 2006, stem cell researcher Shinya Yamanaka presented a striking finding at a scientific conference. Working at Kyoto University and the Japan Science and Technology Agency, he announced that four specific factors could convert a mouse fibroblast into a pluripotent stem cell. He confirmed one factor was Oct4 but kept the other three a secret, famously saying he lacked the courage to reveal them yet.
The Four Factors Published in Cell
Just months later, in August 2006, Yamanaka and his colleague Kazutoshi Takahashi published the landmark findings in Cell. The four reprogramming factors were Oct3/4, Sox2, c-Myc, and Klf4. Consequently, this publication became one of the most cited papers in modern biology.
2007: Human Cells Reprogrammed for the First Time
Within a year, two independent research teams made another major leap. Both groups demonstrated that the same reprogramming approach worked on adult human cells.
Yamanaka’s team delivered the four Yamanaka factors into human skin cells using retrovirus-mediated transfection. They then differentiated the resulting iPSCs into neural and cardiac cells. Meanwhile, James Thomson’s team at the University of Wisconsin, Madison took a different path. They used a lentivirus to deliver an alternative set of four transcription factors: Oct4, Sox2, Nanog, and Lin28.
Both breakthroughs generated tremendous excitement across the research community. Thomson predicted that many labs would soon shift focus from embryonic stem cells to iPSCs. Researchers acknowledged early limitations, particularly the use of retroviruses. Nevertheless, these results provided clear proof of concept for iPSC research in humans.
2008: Patient-Derived iPSCs Enter the Picture
ALS Cells Reprogrammed Into Motor Neurons
For the first time, scientists reprogrammed cells taken directly from a patient with amyotrophic lateral sclerosis (ALS) into iPSCs. They then differentiated these cells into healthy motor neurons. Researchers celebrated this as a major accomplishment, even while noting important limitations. For instance, it remained unclear whether the neurons would eventually develop ALS pathology or form connections with muscle fibers in a living organism.
Still, the team expressed optimism. Patient-derived iPSCs offered a new window into the molecular mechanisms driving ALS. Moreover, scientists hoped to use them as platforms for testing potential therapeutic compounds.
2009: A Safer, Protein-Based Reprogramming Method
Eliminating the Risk of DNA Integration
Earlier iPSC methods used retroviruses to deliver reprogramming factors, which carried the risk of foreign DNA integrating into the genome. Such integration could trigger disease-causing genetic changes. Researchers explored alternatives — non-integrating adenoviruses, transient plasmids, and piggyBac transposon systems — but these still required DNA delivery.
In 2009, pharmaceutical chemist Sheng Ding at the Scripps Research Institute developed a fully protein-based reprogramming method. His team purified the protein versions of the four Yamanaka factors and combined them with valproic acid, a histone deacetylase inhibitor. Together, these reprogrammed mouse embryonic fibroblasts into iPSCs without touching the genome. Other researchers quickly recognized this as a safer path toward clinical applications.
2012: The Nobel Prize Validates the Field
Just six years after Yamanaka’s initial discovery, the scientific community received formal recognition of iPSC research’s importance. In 2012, Shinya Yamanaka and developmental biologist John Gurdon of the Gurdon Institute jointly won the Nobel Prize in Physiology or Medicine.
Their award honored the discovery that adult cells can be reprogrammed into a pluripotent state. George Daley of Harvard Medical School noted that the two scientists fundamentally changed how researchers think about cellular specialization. Gurdon had earlier shown that transferring a nucleus from an adult frog cell into a frog egg produced a viable tadpole. This proved that adult cells retain embryonic developmental potential — a finding that set the stage for Yamanaka’s work.
2014: Clinical Trials and iPSC Banking Take Shape
Eye Disease Trials Launch in Japan and the US
By 2013, Japanese researchers launched the world’s first iPSC-based clinical trial, targeting age-related macular degeneration (AMD). In this condition, retinal pigment epithelial (RPE) cells deteriorate, eventually causing blindness. Researchers took skin cells from six AMD patients, reprogrammed them into iPSCs, and injected the cells back into the patients’ retinas. Similar trials for AMD soon followed in the United States, with many focusing on delivering stem cell-derived RPE cells to protect vision.
iPSC Banks Begin Storing Disease Cell Lines
As iPSC research expanded, specialized biobanks began storing iPSC lines derived from patients with diverse conditions, including Alzheimer’s disease and cardiomyopathy. Researchers found that white blood cells, in addition to skin cells, could also be reprogrammed into iPSCs. This discovery opened the door to large-scale lymphocyte banking. Key questions at the time revolved around economics — storage costs, maintenance fees, and researcher access charges. Most banks initially focused on basic research and drug testing, though many looked ahead to banking therapeutic iPSC lines.
2018: Multiple Therapies Advance to Clinical Trials
From a Single Disease to a Broad Treatment Landscape
By 2018, iPSC-derived therapies entered clinical trials for a wide range of conditions, including Parkinson’s disease, spinal cord injury, endometriosis, heart disease, and macular degeneration. Reaching this milestone required solving several critical challenges. Research teams worked to ensure that iPSC-derived cells would engraft successfully, remain effective inside the body, and avoid triggering tumor formation.
Off-the-Shelf Therapies Reduce Cost and Complexity
Researchers also explored “off-the-shelf” iPSC therapies during this period. One approach reprogrammed donor iPSCs into mesenchymal stem cells, which lack donor-specific antigens. As a result, these cells reduce the risk of immune rejection. Additionally, they cost less to produce than patient-specific iPSC therapies, making them more scalable for widespread clinical use.
2025: Rethinking Oct4 and the Road Ahead
Oct4’s Role Turns Out to Be More Complex
Oct4 earned its reputation as the cornerstone of the Yamanaka cocktail. Hans Schöler had originally identified it as a transcription factor critical to early development and pluripotency maintenance. For years, researchers considered it the most important of the four factors.
However, in 2019, graduate student Sergiy Velychko in Schöler’s group discovered that Oct4 is not actually required to generate iPSCs. Removing it slowed the reprogramming process, but the resulting cells showed higher quality. Moreover, by engineering a more stable Oct4-Sox2 dimer through a Sox2 mutation, the team generated iPSCs from cell types that had previously resisted reprogramming.
AI and Synthetic Factors Point to the Future
Today, researchers continue probing which parts of Oct4 drive reprogramming. Some teams aim to design entirely synthetic reprogramming factors based on those insights. Additionally, artificial intelligence models now assist scientists in optimizing iPSC development protocols. Together, these innovations suggest that the next chapter of iPSC research will be faster, more precise, and more therapeutically powerful than ever before.
